Evaxion presents proof-of-principle for its unique ai model predicting responses to cancer immunotherapy

Copenhagen, denmark, nov. 15, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, presents for the first time its ai model designed to predict patient responses to cancer immunotherapy at the biomarkers & precision oncology europe conference in berlin, germany.
EVAX Ratings Summary
EVAX Quant Ranking